Fujifilm to start phase II clinical trial of Avigan for COVID-19 patients in U.S.

Fujifilm to start phase II clinical trial of Avigan for COVID-19 patients in U.S.
  • Country:
  • Japan

Fujifilm Holdings Corp said it will start phase II clinical trials of its anti-flu drug Avigan for COVID-19 patients in the United States.

The trial will enrol about 50 COVID-19 patients in collaboration with Brigham and Women's Hospital, Massachusetts General Hospital, and the University of Massachusetts Medical School, Fujifilm said on Thursday.

On March 31, Fujifilm announced the start of a phase III clinical trial of Avigan for COVID-19 patients in Japan.

Give Feedback

Use this form for editorial or site feedback. We usually reply within 2 to 3 working days.

By submitting, you agree that we may use your email address to respond.